2026-06-18
Humana (NYSE: HUM) is one of the United States’ largest managed care organisations, deriving approximately 85% of revenues from its Medicare Advantage insurance segment and the remainder from CenterWell, a health services platform spanning primary care clinics, pharmacy, and home health. The company serves roughly 17 to 18 million members, with its core franchise centred on government-sponsored managed care for seniors. It is capital-light relative to revenue but generates thin net margins. Revenue has compounded at roughly 10% annually over four years to $129.7 billion in FY2025, but earnings have collapsed from a $22 peak EPS in 2022 to a GAAP EPS of $9.84 in 2025, burdened by elevated medical-cost ratios and Star Ratings headwinds.
Intrinsic Value Inputs Used
- Adjusted EPS (FY2025, normalized): $17.14
- GAAP EPS (FY2025): $9.84
- FY2026 Adjusted EPS guidance: at least $9.00 (Star Ratings headwind year; not representative of normalised earnings)
- Free cash flow (FY2025): $375 million (severely depressed; FCF was approximately $2.4 billion in FY2024)
- Shares outstanding: approximately 121 million
- Long-term debt: $12.4 billion
- Cash: $4.2 billion
- Dividend per share: $3.54
- Current price: $362
- DCF intrinsic value per share: approximately $253
- MEV midpoint: approximately $240
- PE (Adjusted EPS $17.14): 21.1x
- PE (FY2026 guidance $9.00): 40.2x (trough; not meaningful for valuation)
- PEGY: (Adjusted PE) / (Growth + Yield); dividend yield ~1.0%. PEGY = 21.1 / 15 = 1.4. Modestly overvalued.
DEEP DIVE
Business Understanding
Humana operates as one of the three dominant managed-care organisations in American Medicare Advantage, alongside UnitedHealth and CVS/Aetna. Its business model is straightforward: collect premiums from the federal government (through CMS) and from members, then manage total medical costs below those premiums, pocketing the difference as operating income. The insurer segment accounts for approximately 85% of revenues at $109 to $124 billion, covering around 5.3 million individual Medicare Advantage members as of early 2026 (down from a 2024 peak, then recovering). The CenterWell segment, roughly $22.5 billion in revenues, operates senior primary care clinics, a pharmacy business, and home-health services. Demand is structurally growing: the 65-plus population in the United States is growing at roughly 10,000 per day. The model is durable unless CMS fundamentally restructures Medicare Advantage reimbursement or Star Ratings bonuses, both of which are live political risks. The business model is simple to understand but execution is demanding: cost management, Star Ratings maintenance, and risk-adjusted bidding are the key levers.
Competitive Advantage and Positioning
Humana possesses a genuine, if under-stress, competitive moat. Scale in Medicare Advantage creates data advantages in risk adjustment and care management, and switching costs are meaningful for seniors who build relationships with provider networks and pharmacies. The CenterWell platform deepens the moat: owning primary care clinics creates a vertically integrated care model that can, in theory, manage total cost more effectively than pure insurers. Pricing power exists indirectly through CMS bid cycles; the insurer with the lowest cost structure can offer more attractive benefits and capture membership share. Humana’s main competitors are UnitedHealth Group (which dwarfs it at $372 billion in revenue), CVS/Aetna, Cigna, and Elevance Health. Among these, Humana is the most Medicare Advantage-concentrated, which is both its source of advantage and its vulnerability. The moat is currently narrowing: the collapse of Humana’s Star Ratings from 2024 onward has cost it hundreds of millions of dollars in quality bonuses, directly weakening its ability to offer competitive benefits. The appeal of the Star Ratings lawsuit was rejected in court. Moat recovery depends on restoring ratings, which management expects to begin in 2027 benefit year.
Financial Strength, Profitability
The deterioration in profitability over three years is striking. Revenue has grown robustly (from $92.9 billion in 2022 to $129.7 billion in FY2025, a 40% increase), but GAAP net income has collapsed from $2.8 billion in 2022 to $1.2 billion in FY2025. GAAP EPS has fallen from $22.08 in 2022 to $9.84 in FY2025, a decline of 55%. Adjusted EPS of $17.14 is more flattering but still below 2022 peaks. Net profit margin is 0.9%, which is thin for a business of this complexity and regulatory exposure. Operating margin of approximately 2.1% places Humana near the bottom of its managed-care peer group. ROE is approximately 6.7% and ROA is negligible, both far below Humana’s historical standards. The core driver of margin compression is the benefit ratio: the FY2025 Insurance segment benefit ratio of 90.4% leaves only a 9.6% gross margin from which to cover overhead, interest, and taxes. Peer comparison is unfavorable; UnitedHealth and Elevance Health maintain higher margins through more diversified revenue streams.
Financial Strength, Balance Sheet
The balance sheet is serviceable but not a fortress. Total assets stood at approximately $48.9 billion at year-end 2025, against total liabilities of $31.2 billion. Long-term debt of $12.4 billion is sizeable; the debt-to-equity ratio of approximately 0.70x is manageable in normal conditions. Cash of $4.2 billion provides near-term liquidity, but free cash flow at $375 million in FY2025 (an 84% year-over-year decline from approximately $2.4 billion in FY2024) is a serious concern. Interest coverage, with operating income of roughly $1.45 billion against net interest costs of approximately $631 million, sits at around 2.3x: thin under stress. Goodwill and intangibles exist but are not bloated relative to assets. Pension obligations are not a disclosed material concern. The balance sheet can sustain the current operating trough, but a prolonged period of near-zero free cash flow would force prioritisation between debt service, the dividend ($3.54 per share, approximately $430 million per year), and growth investment.
Financial Strength, Cash Flow
This is the most alarming section of the analysis. Free cash flow collapsed to $375 million in FY2025, down from approximately $2.4 billion in FY2024 and from even higher levels in 2022 to 2023. Operating cash flow in the first nine months of 2025 was $2.6 billion (full-year operating cash flow was thus modest), while capital expenditure of $546 million consumed much of it. Owner earnings, approximating GAAP net income plus depreciation minus maintenance capex, are roughly in the $1.5 to $1.8 billion range, but even this is substantially below the $3 to $4 billion range of two to three years ago. The dividend payout ratio relative to free cash flow is dangerously above 100% at current free cash flow levels, suggesting either the dividend is at risk or free cash flow must recover materially. Management has signalled minimal share repurchases in 2026 to preserve capital, consistent with a balance sheet under strain.
Margin of Safety
There is no margin of safety at $362 per share. Both the DCF estimate ($253) and MEV estimate ($240) place intrinsic value well below the current price. The stock would need to fall approximately 33 to 34% from current levels to reach intrinsic value, and a further 20 to 30% discount would be needed to create an adequate margin of safety for a value investor. Even using the most generous interpretation of adjusted earnings ($17.14) and assuming a full normalisation of margins by 2027 to 2028, the 16-year compound return path from $362 does not reach 9% annually under base-case assumptions. The absence of positive free cash flow further undermines the valuation case: the company is not generating the cash its reported earnings might suggest.
Mispricing Thesis
Why is the stock at $362? The market appears to be discounting a partial recovery scenario: Medicare Advantage membership grew approximately 20% in January 2026 (to roughly 6.28 million individuals), signalling that Humana’s customer-focused benefit redesign is working. The 25% projected MA membership growth in 2026 is genuine and material. Investors may be looking through the 2026 trough (guided EPS of at least $9.00) to a 2027 to 2028 normalised earnings scenario of $20 to $25 per share. At 15x $22, that is $330 per share in 2027, which discounted back to today at a modest rate produces a price close to current levels. The market is not pricing in fundamental value today; it is pricing in an optimistic recovery. That recovery is plausible but carries meaningful execution risk, regulatory risk, and timing risk. The gap is not a classic value mispricing; it is speculative recovery pricing. There is no catalyst that forces a rapid realisation of value unless Star Ratings improve ahead of schedule.
Management and Capital Allocation
Jim Rechtin, appointed CEO in 2023, has stabilised the narrative and shown operational discipline. Value creation initiatives have delivered real cost savings, and the CenterWell build-out is strategically coherent. However, capital allocation has been suboptimal during the crisis: share repurchases of only $151 million in FY2025 (down from over $800 million in prior years) and a maintained dividend in the face of near-zero free cash flow both raise questions. The acquisition of The Villages Health and MaxHealth for CenterWell expansion is strategically sound but adds execution complexity at an already difficult moment. The gap between GAAP EPS ($9.84) and adjusted EPS ($17.14) — $7.30 per share in add-backs — is large and deserves scrutiny; while many adjustments are legitimate (amortisation, put/call valuations), the magnitude requires investor vigilance. Executive pay at $18.9 million for the CFO is generous relative to current shareholder returns.
Long-Term Outlook
The long-term case for Medicare Advantage as a business is sound: the ageing US population, government preference for cost-managed alternatives to traditional Medicare, and a deeply embedded distribution ecosystem all support continued industry growth. Humana’s integrated model with CenterWell has genuine potential to reduce total cost of care and earn higher quality bonuses over time. However, “stronger in 5 to 10 years” is conditional on three things going right: Star Ratings recovery by 2027, successful CenterWell margin maturation through its J-curve, and a stable regulatory environment for CMS reimbursement. All three carry real risk. The Medicaid expansion into 13 states is optionality but will be a drag on earnings in the near term. Disruption from value-based care competitors (Oak Street, which was acquired by CVS, for example) is a structural threat to CenterWell. Humana is not a cyclical business, but it is highly sensitive to regulatory cycles, which can be more abrupt and less predictable than economic cycles.
Risk Assessment
The primary risk is permanent impairment of earnings power through a multi-year period of below-market Star Ratings. Stars determine quality bonuses from CMS, which can represent hundreds of millions of dollars in annual income. Humana lost its lawsuit to restore 2025 Star Ratings and is on appeal, with no assurance of success. A second material risk is further CMS rate cuts or structural reform of Medicare Advantage pricing, which is a perennial political topic and has become more acute as the programme’s cost to the federal government has grown. Customer concentration risk is extreme: essentially all earnings flow from one government programme. Regulatory risk is thus existential in the long run if CMS materially restructures the programme. There is also balance-sheet risk: at 2.3x interest coverage with near-zero free cash flow, a sharp rise in medical costs or a recession-induced membership decline could require an equity raise. Finally, competitive risk from UnitedHealth’s OptumHealth vertical integration is a persistent pressure on Humana’s long-term market share.
Investment Thesis
Humana is a temporarily impaired business, not a permanently broken one. The Medicare Advantage franchise is real and valuable, and the CenterWell build-out is strategically correct. However, the stock at $362 prices in a recovery scenario (2027 to 2028 earnings of $20 to $25 per share at 14 to 16x) with very little margin of safety. If the recovery is delayed by one to two years, or if CMS introduces further rate pressure, the stock could fall materially further. The thesis is invalidated by: another Star Ratings decline, CMS structural reimbursement cuts, a sustained elevated benefit ratio above 91%, or free cash flow remaining near zero beyond 2026. The thesis is validated by: Star Ratings restoration, benefit ratio returning below 88%, and CenterWell achieving profitability. At $362, the risk-reward is asymmetric to the downside. An investor paying $362 needs perfect execution of a multi-year recovery to reach a 9% annual return.
Red Flag Scan
- Collapsing free cash flow: FCF fell 84% in one year to $375 million.
- Dividend covered by earnings on adjusted basis only; not by free cash flow.
- Rising debt without corresponding earnings growth.
- GAAP to adjusted EPS gap of $7.30 per share; add-backs require close monitoring.
- Star Ratings litigation failed; regulatory risk unresolved.
- Member concentration in one government programme (Medicare Advantage).
- Serial small acquisitions (The Villages Health, MaxHealth) during a period of balance sheet stress.
- Adjusted EPS guidance for 2026 ($9.00) represents a further 47% decline from FY2025 adjusted EPS, suggesting the trough may not yet be reached.
Weighted SWOT
Strengths
- Scale and brand in Medicare Advantage: weight 25%, score 8.0 — second-largest MA insurer with deep distribution
- CenterWell vertical integration: weight 20%, score 6.5 — differentiated long-term model, early-stage but strategic
- Ageing demographic tailwind: weight 15%, score 9.0 — structural demand growth of 10,000 new Medicare-eligible Americans per day
- Revenue scale ($129.7 billion): weight 10%, score 7.5 — creates data and purchasing power advantages
- Switching costs for senior members: weight 10%, score 7.0 — high inertia once enrolled and pharmacy relationships established
Weighted Strength Score: (25×8 + 20×6.5 + 15×9 + 10×7.5 + 10×7) / 80 = (200+130+135+75+70) / 80 = 7.63
Weaknesses
- Near-zero free cash flow: weight 25%, score 2.0 — existential concern for capital allocation
- Collapsed Star Ratings: weight 25%, score 2.5 — directly reduces CMS bonus income
- GAAP profit margin below 1%: weight 20%, score 2.5 — very thin margin of error
- Revenue concentration in one government programme: weight 15%, score 3.0 — makes all risks systemic
- Large GAAP to adjusted earnings gap: weight 15%, score 3.5 — credibility concern
Weighted Weakness Score: (25×2 + 25×2.5 + 20×2.5 + 15×3 + 15×3.5) / 100 = (50+62.5+50+45+52.5) / 100 = 2.60
Opportunities
- MA membership growth of 25% in 2026: weight 30%, score 7.5 — genuine and confirmed
- CenterWell margin maturation: weight 25%, score 6.0 — multi-year J-curve improvement
- Medicaid expansion to 13 states: weight 20%, score 5.5 — additive but early
- Star Ratings recovery in 2027 benefit year: weight 15%, score 5.0 — conditional and not guaranteed
- CMS Cost Plus pharmacy partnership: weight 10%, score 5.5 — drug cost innovation
Weighted Opportunity Score: (30×7.5 + 25×6 + 20×5.5 + 15×5 + 10×5.5) / 100 = (225+150+110+75+55) / 100 = 6.15
Threats
- Structural CMS reimbursement reform: weight 30%, score 3.0 — bipartisan political pressure
- Prolonged Star Ratings disadvantage: weight 25%, score 3.5 — court ruled against Humana
- Competitive pressure from UnitedHealth vertical integration: weight 20%, score 4.0
- Rising medical cost trend (benefit ratio above 90%): weight 15%, score 3.0
- Dividend cut risk if FCF does not recover: weight 10%, score 4.0
Weighted Threat Score: (30×3 + 25×3.5 + 20×4 + 15×3 + 10×4) / 100 = (90+87.5+80+45+40) / 100 = 3.43
Net SWOT Score: Strengths (7.63) minus Weaknesses (2.60) plus Opportunities (6.15) minus Threats (3.43) = 7.75 out of a possible maximum. Interpretation: the underlying business has genuine strengths and long-term opportunities, but the operational and financial weaknesses are severe enough to offset much of that potential. Net score is positive but the nearer-term picture is negative.
Scenario Valuations
Bear Scenario
Assumptions: Star Ratings do not recover until 2028; CMS introduces an additional 2 to 3% rate cut in 2026 to 2027; benefit ratio stays above 91%; CenterWell losses widen. Normalised adjusted EPS by 2028: $12. Fair PE: 11x. Bear intrinsic value: $132. Entry price: $95 or lower. Exit: if thesis proves wrong and EPS falls below $10 on an adjusted basis, exit at $120.
Base Scenario
Assumptions: Star Ratings partially recover in 2027 benefit year; benefit ratio returns to 89% by 2027; MA membership grows 20 to 25% over two years; CenterWell reaches breakeven. Normalised adjusted EPS by 2027 to 2028: $20 to $22. Fair PE: 14x. Base intrinsic value: $294. Entry price: $200 to $210 (providing approximately 30% discount). Exit: $340 to $370 when approaching fair value, or if EPS exceeds $25.
Bull Scenario
Assumptions: Star Ratings fully restored by 2027; benefit ratio normalises to 87%; CenterWell profitable; MA membership at 7.5 million by 2027; EPS recovery to $26 to $28. Fair PE: 16x. Bull intrinsic value: $432. Entry price: $280 or lower. Exit: $420 to $450 in 2027 to 2028.
Entry and Exit Conditions
Enter at $200 or below (base scenario; approximately 30% discount to base intrinsic value). Do not buy at or above $280 (excessive risk premium required). Begin trimming above $340. Sell in full above $400 or if FY2026 adjusted EPS falls below $8.00 (thesis failure signal).
Buy Price by Target Return (16-year horizon)
Projected exit fair value (base case, 16 years): Normalised EPS by 2041 estimated at $48 (starting from $20 in 2028, compounding at 7% for ~10 years to maturity); fair PE 14x = $672.
- 5% per year: $672 / (1.05)^16 = $672 / 2.183 = $308
- 6% per year: $672 / (1.06)^16 = $672 / 2.540 = $265
- 7% per year: $672 / (1.07)^16 = $672 / 2.952 = $228
- 8% per year: $672 / (1.08)^16 = $672 / 3.426 = $196
- 9% per year: $672 / (1.09)^16 = $672 / 3.970 = $169
- 10% per year: $672 / (1.10)^16 = $672 / 4.595 = $146
At $362, the implied annual return over 16 years is approximately 3.9%, far below the 9% target.
Buy Price by Horizon (9% target)
Exit fair value assumed at $672 in 16 years (base case), scaled for shorter periods using proportional normalised earnings growth.
- 5 years (exit ~$320 in 2031): $320 / (1.09)^5 = $320 / 1.539 = $208
- 7 years (exit ~$390 in 2033): $390 / (1.09)^7 = $390 / 1.828 = $213
- 10 years (exit ~$470 in 2036): $470 / (1.09)^10 = $470 / 2.367 = $199
- 12 years (exit ~$540 in 2038): $540 / (1.09)^12 = $540 / 2.813 = $192
- 14 years (exit ~$606 in 2040): $606 / (1.09)^14 = $606 / 3.342 = $181
- 16 years (exit ~$672 in 2042): $169 (as above)
At $362, no horizon on a 9% target is satisfied under base-case assumptions.
Trim and Exit Prices
Begin trimming: $330 (approaching base intrinsic value; reward-to-risk narrows sharply)
Full exit: $400 (above bull-case near-term intrinsic value; risk of rerating lower exceeds upside)
Stop-loss consideration (thesis failure): $230 (if adjusted EPS guidance falls below $8 for two consecutive years, signalling structural rather than temporary impairment)
Risk Score
| Sub-Factor | Score (1-10, 10=strongest/safest) | Weight |
|---|---|---|
| Financial Stability | 3.5 | 30% |
| Earnings Volatility | 2.5 | 20% |
| Business Model Risk | 4.0 | 20% |
| Macro Sensitivity | 5.5 | 15% |
| Market Risk | 4.0 | 15% |
Risk Score = (0.30 x 3.5) + (0.20 x 2.5) + (0.20 x 4.0) + (0.15 x 5.5) + (0.15 x 4.0)
= 1.05 + 0.50 + 0.80 + 0.825 + 0.60 = 3.78 out of 10
Interpretation: A score of 3.78 signals elevated risk. The primary drags are near-zero free cash flow, extreme earnings volatility (EPS down 55% in three years), and a business model exposed almost entirely to one government programme’s regulatory decisions. Macro sensitivity is moderate because healthcare demand is relatively recession-resistant, but regulatory cycles can be more damaging than economic cycles.
Opportunity Score
| Sub-Factor | Score (1-10) | Weight |
|---|---|---|
| Growth Potential | 6.5 | 30% |
| Unit Economics | 3.0 | 20% |
| Competitive Advantage | 5.5 | 20% |
| Valuation Asymmetry | 2.0 | 20% |
| Catalysts | 5.0 | 10% |
Opportunity Score = (0.30 x 6.5) + (0.20 x 3.0) + (0.20 x 5.5) + (0.20 x 2.0) + (0.10 x 5.0)
= 1.95 + 0.60 + 1.10 + 0.40 + 0.50 = 4.55 out of 10
Interpretation: A score of 4.55 is below average. Long-term growth potential from MA demographics and CenterWell is genuine but offset by severely impaired unit economics (sub-1% net margin, near-zero FCF), negative valuation asymmetry (stock priced above intrinsic value), and catalysts that are either delayed (Stars recovery) or conditional (CMS cooperation). The opportunity is real but the price does not reflect it.
Classification
Humana is best classified as a temporarily impaired stable-growth company. The underlying business is stable (non-cyclical healthcare demand) but is experiencing a multi-year operational disruption from regulatory and cost pressures.
Peter Lynch would classify it as a “stalwart” with temporary problems. He would note the strong franchise and demographic tailwind, but would likely require a PE below 15x on normalised earnings before becoming interested. He would be cautious about a company with a PE above 20x on adjusted earnings when GAAP earnings tell a different story. At $362, Lynch would say the price is too high for the uncertainty involved.
Charlie Munger would classify it as a good business at a bad price. He would admire the competitive position in Medicare Advantage and the integrated CenterWell model, which reflects the kind of durable, deeply embedded franchise he valued. However, Munger’s discipline was to wait for a fair price. With intrinsic value well below the current price and no margin of safety, Munger would decline to invest and wait for the market to offer a better entry.
Data Used Versus Ignored
Used:
- FY2025 revenue ($129.7 billion), GAAP EPS ($9.84), adjusted EPS ($17.14)
- FY2026 guidance: adjusted EPS at least $9.00, MA membership growth approximately 25%
- Free cash flow FY2025 ($375 million), FY2024 (~$2.4 billion)
- Long-term debt ($12.4 billion), cash ($4.2 billion), D/E (0.70x)
- Benefit ratio FY2025 (90.4%), operating margin (2.1%), net margin (0.9%)
- Shares outstanding (121 million), dividend ($3.54)
- Historical EPS: 2022 ($22.08), 2023 ($20.00), 2024 ($9.98), 2025 ($9.84)
- Star Ratings history and litigation outcome
- CenterWell patient growth (100,600 in 2025)
- Analyst consensus (26 analysts, Hold, price target $301.63)
Ignored or de-weighted:
- TTM revenue ($137.2 billion): used FY2025 annual figures for consistency
- Short-term trading metrics (beta, short interest): not relevant to 16-year horizon
- Quarterly fluctuations: noise around the structural trend
- EBITDA multiples: less relevant for insurance companies where cash flow from operations is the key metric
- 2026 GAAP EPS guidance ($8.36 revised): used as a signal of trough depth, not for valuation
Summary and Verdict
Humana is a franchise business in permanent distress mode, not a permanently broken one. The Medicare Advantage platform is real, the demographic tailwind is undeniable, and the CenterWell strategy is coherent. But the stock at $362 is priced for a recovery that is not yet delivered, not yet fully visible, and carries substantial regulatory tail risk.
The numbers are unambiguous: DCF intrinsic value of approximately $253, MEV of approximately $240, a 16-year buy price for 9% returns of $169, near-zero free cash flow in FY2025, a GAAP EPS of $9.84 against a stock price of $362 (37x GAAP PE), and 2026 guidance signalling further earnings deterioration. No version of a 9% annual return over 16 years is achievable from $362 under base-case or bear-case scenarios. Even under a bull scenario with full margin restoration, the 16-year path is below 9%.
The analyst consensus price target of $301.63 is itself 17% below current price, implying the professional community already finds the stock expensive.
Final verdict: Avoid / Sell. The stock does not meet the 9% over 16 years investment goal at the current price of $362. A patient investor would wait for the stock to reach $170 to $200 before building a position, which would require either a fundamental deterioration in the business (not desired) or a market overreaction that disconnects the price from even a modest recovery scenario. Current holders who own at higher prices should consider whether their thesis has been validated or invalidated by the Star Ratings developments and should review against their own cost basis.
Target prices: Do not buy above $200. Consider initiating at $170 to $185. Intrinsic fair value $240 to $253.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always perform your own due diligence or consult with a financial advisor before making investment decisions.
